GSK_ Annual_Report_2021-22

GlaxoSmithKline Pharmaceuticals Limited | Annual Report 2021-22 184 (a) Equity share capital ( ` in lakhs) As at March 31, 2022 As at March 31, 2021 No. of Shares Amount No. of Shares Amount Balance at the beginning of the reporting period 960,000 96.00 960,000 96.00 Changes in equity share capital during the year - - - - Balance at the end of the reporting period 960,000 96.00 960,000 96.00 (b) Other equity ( ` in lakhs) Reserves and Surplus Items of Other comprehensive income Total Other Equity Capital reserve General reserve Retained Earnings Remeasurements of the net defined benefit plans Balance at 1 April 2021 2.91 1,006.01 (540.76) - 4,68.16 Total Comprehensive income Profit/(loss) for the year - - 419.35 - 419.35 Other Comprehensive Income for the year - - - - - Transactions with owners of the company Dividend on Equity Shares - - - - - Dividend Distribution Tax - - - - - Balance at the end of the reporting period March 31, 2022 2.91 10,06.01 (1,21.41) - 8,87.51 Balance at April 1, 2020 2.91 1,006.01 (5,98.74) - 4,10.18 Total Comprehensive income Profit/(loss) for the year - - 57.98 - 57.98 Other Comprehensive Income for the year - - - - - Transactions with owners of the company Dividend on Equity Shares - - - - - Dividend Distribution Tax - - - - - Balance at the end of the reporting period March 31, 2021 2.91 10,06.01 (5,40.76) - 4,68.16 The accompanying notes are an integral part of these financial statements As per our report of even date attached For and on behalf of the Board For CORNELIUS & DAVAR CHARTERED ACCOUNTANTS (Firm’s Registration No.101963W) S. Venkatesh Director DIN: 07263117 J. Chandy Director DIN: 09530618 RUSTOM D. DAVAR (PARTNER) Membership No. F10620 R. Mota Company Secretary ACS 38473 Place : Mumbai Date: May 9, 2022 UDIN: 22010620AIQVGD8202 Place : Mumbai Date: May 9, 2022 BIDDLE SAWYER LIMITED Statement of Changes in Equity